Renal cell carcinoma bone metastases: clinical advances
Bone is a common site of metastatic spread in patients with advanced renal cell carcinoma (RCC) occurring in around one-third of patients enrolled in clinical trials evaluating modern systemic therapies for this disease. Until recently, limited systemic therapeutic options were available for advance...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2010-03-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/1758834009358417 |
id |
doaj-54094625dc28476698e1fb6e12a8d436 |
---|---|
record_format |
Article |
spelling |
doaj-54094625dc28476698e1fb6e12a8d4362020-11-25T04:02:41ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83402010-03-01210.1177/1758834009358417Renal cell carcinoma bone metastases: clinical advancesChakshu SahiJennifer J. KnoxMark ClemonsAnthony M. JoshuaReuben BroomBone is a common site of metastatic spread in patients with advanced renal cell carcinoma (RCC) occurring in around one-third of patients enrolled in clinical trials evaluating modern systemic therapies for this disease. Until recently, limited systemic therapeutic options were available for advanced RCC. Nowadays, a quiver of agents have demonstrated activity, including compounds targeting the vascular endothelial growth factor (VEGF) axis and those targeting the mammalian target of rapamycin (mTOR). Despite a detailed biological understanding of how these drugs work, their effect on bony metastases is less clear. Data suggesting that bisphosphonates (namely zoledronic acid) benefit patients with bone metastases from advanced RCC was gathered prior to the targeted therapy era; therefore, there is some uncertainty about their role in patients on modern RCC therapies. This review summarizes the current targeted therapies registered for use in advanced RCC and postulates how some of them might affect the behavior of bone metastases. It also explores the data available on the role of bisphosphonates for bone metastases from RCC, describes methods of assessing response to therapy for bone metastases and delineates future expectations for the treatment of bone metastases from advanced RCC.https://doi.org/10.1177/1758834009358417 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Chakshu Sahi Jennifer J. Knox Mark Clemons Anthony M. Joshua Reuben Broom |
spellingShingle |
Chakshu Sahi Jennifer J. Knox Mark Clemons Anthony M. Joshua Reuben Broom Renal cell carcinoma bone metastases: clinical advances Therapeutic Advances in Medical Oncology |
author_facet |
Chakshu Sahi Jennifer J. Knox Mark Clemons Anthony M. Joshua Reuben Broom |
author_sort |
Chakshu Sahi |
title |
Renal cell carcinoma bone metastases: clinical advances |
title_short |
Renal cell carcinoma bone metastases: clinical advances |
title_full |
Renal cell carcinoma bone metastases: clinical advances |
title_fullStr |
Renal cell carcinoma bone metastases: clinical advances |
title_full_unstemmed |
Renal cell carcinoma bone metastases: clinical advances |
title_sort |
renal cell carcinoma bone metastases: clinical advances |
publisher |
SAGE Publishing |
series |
Therapeutic Advances in Medical Oncology |
issn |
1758-8340 |
publishDate |
2010-03-01 |
description |
Bone is a common site of metastatic spread in patients with advanced renal cell carcinoma (RCC) occurring in around one-third of patients enrolled in clinical trials evaluating modern systemic therapies for this disease. Until recently, limited systemic therapeutic options were available for advanced RCC. Nowadays, a quiver of agents have demonstrated activity, including compounds targeting the vascular endothelial growth factor (VEGF) axis and those targeting the mammalian target of rapamycin (mTOR). Despite a detailed biological understanding of how these drugs work, their effect on bony metastases is less clear. Data suggesting that bisphosphonates (namely zoledronic acid) benefit patients with bone metastases from advanced RCC was gathered prior to the targeted therapy era; therefore, there is some uncertainty about their role in patients on modern RCC therapies. This review summarizes the current targeted therapies registered for use in advanced RCC and postulates how some of them might affect the behavior of bone metastases. It also explores the data available on the role of bisphosphonates for bone metastases from RCC, describes methods of assessing response to therapy for bone metastases and delineates future expectations for the treatment of bone metastases from advanced RCC. |
url |
https://doi.org/10.1177/1758834009358417 |
work_keys_str_mv |
AT chakshusahi renalcellcarcinomabonemetastasesclinicaladvances AT jenniferjknox renalcellcarcinomabonemetastasesclinicaladvances AT markclemons renalcellcarcinomabonemetastasesclinicaladvances AT anthonymjoshua renalcellcarcinomabonemetastasesclinicaladvances AT reubenbroom renalcellcarcinomabonemetastasesclinicaladvances |
_version_ |
1724442516140326912 |